Atezolizumab Plus Bevacizumab Versus Sintilimab Plus Bevacizumab With Transarterial Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Unresectable Hepatocellular Carcinoma: A Multicenter Real-World Study
Conditions: Hepatocellular Carcinoma Interventions: Drug: Atezolizumab combined with Bevacizumab; Drug: Sintilimab combined with Bevacizumab; Procedure: Transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy Sponsors: Sun Yat-sen University Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Avastin | Cancer & Oncology | Carcinoma | Chemotherapy | Hepatocellular Carcinoma | Liver Cancer | Research | Study